Skip to content
value.today

Immix Biopharma, Inc.

IMMX
$675 Mmarket cap on Oct 28, 2026+457.6% since Jan 2024
Compare
World rank
#11,268
Revenue
—
For year ending December-2025
Net income
$-29 M
SEC filing
Employees
21
As of March 20, 2026
SEC filing

Immix Biopharma, Inc. in brief

Immix Biopharma, Inc. is a listed company in the Biotechnology industry, based in Los Angeles, California, USA. Its market value was $675 M on 28 October 2026, which makes it the 11,268th largest listed company in the world and the 2,337th largest in the USA on this site. It employs about 21 people and Ilya M. Rachman is its chief executive. Its shares trade under the symbol IMMX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Immix Biopharma, Inc.

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the application of chimeric antigen receptor cell therapy in light chain (AL) Amyloidosis and other serious diseases. Our lead cell therapy candidate is CAR-T NXC-201, currently being evaluated in our ongoing United States Phase 1b/2 NEXICART-2 (NCT06097832) clinical trial and an ex-U.S. phase 1b/2a NEXICART-1 (NCT04720313) clinical trial. NEXICART-2 is expected to enroll 40 patients, with final readout and Biologics License Application submission planned thereafter.

NXC-201 has been awarded Regenerative Medicine Advanced Therapy Designation by the FDA, Orphan Drug Designation by both the FDA and European Commission in AL Amyloidosis and, most recently, in January 2026, Breakthrough Therapy designation by the FDA for the treatment of relapsed/refractory AL amyloidosis.

From the company's annual report filed with the US SEC: read the report

Immix Biopharma, Inc. timeline

2 events, 2021
  1. 2021
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 17 December 2021; shares registered for exchange trading on 13 December 2021.

Events of Immix Biopharma, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$212 M$424 M$636 M$848 M2023202420252026

World rank over time

▲ up 16,286 places since 2022
2022-12-25: #27585#27,58520222023-07-30: #27297#27,29720232024-01-05: #20452#20,45220242026-03-08: #7063#7,06320262026-08-01: #10345#10,34520262026-10-13: #10604#10,60420262026-10-28: #11299#11,2992026

Rank in USA: #5,083 (Dec 2022) · #4,970 (Jul 2023) · #3,572 (Jan 2024) · #1,238 (Mar 2026) · #2,245 (Aug 2026) · #2,238 (Oct 2026) · #2,339 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
7.2×
Free cash flow yield
-3.7%
Net margin
—
Operating margin
—
Return on equity
-31.4%
Liabilities / assets
10.5%
Profit per employee
$-1.4 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2020: revenue —, net income $-1M—FY20Fiscal year ending Dec 2021: revenue —, net income $-24M—FY21Fiscal year ending Dec 2022: revenue —, net income $-8M—FY22Fiscal year ending Dec 2023: revenue —, net income $-15M—FY23Fiscal year ending Dec 2024: revenue —, net income $-22M—FY24Fiscal year ending Dec 2025: revenue —, net income $-29M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-30M$-29M—
Dec 2024——$-23M$-22M—
Dec 2023——$-16M$-15M—
Dec 2022——$-8M$-8M—
Dec 2021——$-1M$-24M—
Dec 2020——$-0M$-1M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-24M$1M$-25M$-0.89—
Dec 2024$-15M$1M$-16M$-0.76—
Dec 2023$-11M$0M$-11M$-0.89—
Dec 2022$-7M——$-0.59—
Dec 2021$-2M$0M$-2M$-6.64—
Dec 2020$-0M——$-0.34—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-5M—Dec ’24Three months to Mar 2025: revenue —, net income $-5M—Mar ’25Three months to Jun 2025: revenue —, net income $-7M—Jun ’25Three months to Sep 2025: revenue —, net income $-8M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-11M—Dec ’25Three months to Mar 2026: revenue —, net income $-10M—Mar ’26Three months to Jun 2026: revenue —, net income $-12M—Jun ’26Three months to Sep 2026: revenue —, net income $-14M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-14M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Immix Biopharma, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-30 M
Net income
$-29 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$105 M
Total liabilities
$11 M
Total equity
$94 M

As of December-2025

Top 100 institutional investors in Immix Biopharma, Inc.#

As of Sep 30, 2026
137 institutions held 65.9 M shares (about 78.6% of the shares outstanding) on Sep 30, 2026. The ten largest hold 50.0%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Immix Biopharma, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Janus Henderson Group Ltd.12,069,267—14.40%$126 MNov 16, 2026
2Eventide Asset Management, LLC5,186,534+1,295,515 (+33.30%)6.19%$54 MNov 13, 2026
3Saturn V Capital Management LP4,661,115+2,686 (+0.06%)5.56%$48 MNov 16, 2026
4BlackRock, Inc.4,539,819+1,549,847 (+51.83%)5.42%$47 MNov 13, 2026
5State Street Corp3,304,389+307,454 (+10.26%)3.94%$34 MNov 12, 2026
6Vanguard Capital Management LLC3,002,000+494,878 (+19.74%)3.58%$31 MNov 13, 2026
7Opaleye Management Inc.2,825,000+480,000 (+20.47%)3.37%$29 MNov 16, 2026
8Balyasny Asset Management L.P.2,642,437+2,225,210 (+533.33%)3.15%$27 MNov 16, 2026
9Ameriprise Financial Inc1,860,770+1,341,889 (+258.61%)2.22%$19 MNov 16, 2026
10Marshall Wace, LLP1,854,215+59,307 (+3.30%)2.21%$19 MNov 13, 2026
11Franklin Templeton Inc1,787,301+818,181 (+84.43%)2.13%$19 MNov 12, 2026
12Price T Rowe Associates Inc /MD/1,749,800+9,881 (+0.57%)2.09%$18 MNov 16, 2026
13Wellington Management Group LLP1,650,048+176,639 (+11.99%)1.97%$17 MNov 16, 2026
14Geode Capital Management, LLC1,440,734+239,637 (+19.95%)1.72%$15 MNov 6, 2026
15Alliancebernstein L.P.1,322,449+1,283,159 (+3265.87%)1.58%$14 MNov 16, 2026
16Velan Capital Investment Management LP1,085,0000 (0.00%)1.29%$11 MNov 16, 2026
17Bleichroeder LP1,000,0000 (0.00%)1.19%$10 MNov 13, 2026
18Citadel Advisors LLC931,361+425,204 (+84.01%)1.11%$10 MNov 16, 2026
19Millennium Management LLC865,940-1,200,486 (-58.09%)1.03%$9 MNov 16, 2026
20Aberdeen Group plc818,674New0.98%$9 MNov 10, 2026
21Adage Capital Partners GP, L.L.C.727,272New0.87%$8 MNov 16, 2026
22Vanguard Portfolio Management LLC607,678+323,967 (+114.19%)0.72%$6 MNov 13, 2026
23Blue Owl Capital Holdings LP602,047+164,495 (+37.59%)0.72%$6 MNov 13, 2026
24Northern Trust Corp521,279+103,228 (+24.69%)0.62%$5 MNov 16, 2026
25LGT Fund Management Co Ltd.461,159+44,565 (+10.70%)0.55%$5 MNov 13, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Immix Biopharma, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Alyeska Investment Group, L.P.454,545New0.54%$5 MNov 16, 2026
27Monashee Investment Management LLC450,000New0.54%$5 MNov 6, 2026
28Vanguard Fiduciary Trust Co445,754+39,722 (+9.78%)0.53%$5 MNov 13, 2026
29Bank Of America Corp /de/429,320+16,175 (+3.92%)0.51%$4 MNov 16, 2026
30Sphera Funds Management LTD.355,800+85,800 (+31.78%)0.42%$4 MNov 16, 2026
31Institute for Wealth Management, LLC.340,002+2,450 (+0.73%)0.41%$4 MNov 6, 2026
32Picton Mahoney Asset Management333,247New0.40%$3 MNov 9, 2026
33Longaeva Partners L.P.318,181New0.38%$3 MNov 16, 2026
34Qube Research & Technologies Ltd309,539+167,575 (+118.04%)0.37%$3 MNov 13, 2026
35Morgan Stanley292,844+133,370 (+83.63%)0.35%$3 MNov 13, 2026
36Bank of New York Mellon Corp288,149+52,429 (+22.24%)0.34%$3 MNov 5, 2026
37Invesco Ltd.279,143+256,825 (+1150.75%)0.33%$3 MNov 12, 2026
38Seven Grand Managers, LLC259,597+4,597 (+1.80%)0.31%$3 MNov 16, 2026
39Informed Momentum Co LLC239,127+146,302 (+157.61%)0.29%$2 MNov 16, 2026
40KVP Capital Advisors, LP230,4230 (0.00%)0.27%$2 MNov 16, 2026
41TD Asset Management Inc214,0900 (0.00%)0.26%$2 MNov 13, 2026
42D. E. Shaw & Co., Inc.207,720+114,614 (+123.10%)0.25%$2 MNov 16, 2026
43Charles Schwab Investment Management Inc192,478+65,222 (+51.25%)0.23%$2 MNov 16, 2026
44UBS Group AG186,502-1,755,315 (-90.40%)0.22%$2 MNov 10, 2026
45Goldman Sachs Group Inc130,696-43,411 (-24.93%)0.16%$1 MNov 16, 2026
46Manufacturers Life Insurance Company, The127,514-19,340 (-13.17%)0.15%$1 MNov 13, 2026
47Nuveen, LLC125,122+22,143 (+21.50%)0.15%$1 MNov 10, 2026
48Rafferty Asset Management, LLC89,303+30,817 (+52.69%)0.11%$1 MNov 13, 2026
49Moore Capital Management, LP89,069New0.11%$1 MNov 16, 2026
50Tocqueville Asset Management L.P.87,350-1,200 (-1.36%)0.10%$1 MNov 13, 2026
51Bridgeway Capital Management, LLC80,0000 (0.00%)0.10%$1 MNov 16, 2026
52Maven Securities LTD76,000New0.09%$1 MNov 13, 2026
53Squarepoint Ops LLC74,242+4,180 (+5.97%)0.09%$1 MNov 9, 2026
54Aquatic Capital Management LLC74,142New0.09%$1 MNov 16, 2026
55United Capital Financial Advisors, LLC70,686+4 (+0.01%)0.08%$1 MNov 12, 2026
56Susquehanna International Group, LLP66,058+27,327 (+70.56%)0.08%$1 MNov 16, 2026
57Rhumbline Advisers65,127+14,183 (+27.84%)0.08%$1 MNov 10, 2026
58J. Goldman & Co LP63,954-134,778 (-67.82%)0.08%$1 MNov 16, 2026
59Magnetar Financial LLC54,524+43,570 (+397.75%)0.07%$1 MNov 13, 2026
60Gsa Capital Partners LLP51,461+31,588 (+158.95%)0.06%$1 MNov 16, 2026
61Deutsche Bank AG\51,339+10,478 (+25.64%)0.06%$1 MNov 6, 2026
62Prelude Capital Management, LLC48,540New0.06%$1 MNov 16, 2026
63SEI Investments Co45,844-21,504 (-31.93%)0.05%$0 MNov 10, 2026
64Harvest Investment Services, LLC44,737New0.05%$0 MNov 12, 2026
65Citigroup Inc42,864-27,790 (-39.33%)0.05%$0 MNov 4, 2026
66Vanguard Global Advisers, LLC42,222+20,127 (+91.09%)0.05%$0 MNov 13, 2026
67Virtus Investment Advisers, LLC37,554-1,167 (-3.01%)0.04%$0 MNov 12, 2026
68Jpmorgan Chase & Co37,378+17,803 (+90.95%)0.04%$0 MNov 12, 2026
69MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.35,457+9,828 (+38.35%)0.04%$0 MNov 16, 2026
70Private Advisor Group, LLC35,429+104 (+0.29%)0.04%$0 MNov 10, 2026
71Wells Fargo & Company/mn35,285-78,035 (-68.86%)0.04%$0 MNov 16, 2026
72Certuity, LLC35,0000 (0.00%)0.04%$0 MNov 2, 2026
73Optimize Financial Inc.34,626New0.04%$0 MNov 12, 2026
74MetLife Investment Management, LLC34,426+9,494 (+38.08%)0.04%$0 MNov 16, 2026
75Engineers Gate Manager LP34,173+16,343 (+91.66%)0.04%$0 MNov 16, 2026
76Profund Advisors LLC31,431+2,126 (+7.25%)0.04%$0 MOct 29, 2026
77American Century Companies Inc30,580New0.04%$0 MNov 12, 2026
78C2P Capital Advisory Group, LLC d.b.a. Prosperity Capital Advisors30,113New0.04%$0 MOct 14, 2026
79Bank Of Nova Scotia29,400New0.04%$0 MNov 13, 2026
80Arrowstreet Capital, Limited Partnership27,056New0.03%$0 MNov 13, 2026
81State Of Wisconsin Investment Board24,834New0.03%$0 MNov 16, 2026
82Sowell Financial Services LLC24,608New0.03%$0 MOct 23, 2026
83TritonPoint Partners, LLC24,5260 (0.00%)0.03%$0 MNov 5, 2026
84Concurrent Investment Advisors, LLC24,028+28 (+0.12%)0.03%$0 MOct 16, 2026
85Barclays PLC23,047-30,009 (-56.56%)0.03%$0 MNov 6, 2026
86Imprint Wealth LLC20,938-5,295 (-20.18%)0.03%$0 MNov 16, 2026
87Wealth Watch Advisors, INC20,938New0.03%$0 MNov 16, 2026
88Quent Capital, LLC20,0000 (0.00%)0.02%$0 MNov 13, 2026
89Boothbay Fund Management, LLC19,032New0.02%$0 MNov 16, 2026
90Voloridge Investment Management, LLC18,910New0.02%$0 MNov 16, 2026
91BNP Paribas Financial Markets18,607+12,332 (+196.53%)0.02%$0 MNov 12, 2026
92Virtu Financial LLC16,121-7,726 (-32.40%)0.02%$0 MNov 17, 2026
93Police & Firemen's Retirement System of New Jersey16,065+3,950 (+32.60%)0.02%$0 MNov 9, 2026
94New York State Common Retirement Fund14,300-100 (-0.69%)0.02%$0 MNov 17, 2026
95Commonwealth Equity Services, LLC13,753+933 (+7.28%)0.02%$0 MNov 2, 2026
96Mathes Company, Inc.13,150+2,500 (+23.47%)0.02%$0 MNov 16, 2026
97Kera Capital Partners, Inc.13,0000 (0.00%)0.02%$0 MNov 13, 2026
98XTX Topco Ltd12,378-28,117 (-69.43%)0.01%$0 MNov 16, 2026
99Voya Investment Management LLC11,175New0.01%$0 MNov 10, 2026
100Royal Bank Of Canada10,822+9,466 (+698.08%)0.01%$0 MNov 16, 2026

All 137 institutional investors, with who bought and sold →

Mutual funds holding Immix Biopharma, Inc.#

65 funds hold shares worth $142 M (about 16.9% of the company). Since their previous reports 60 added shares and 1 sold, buying $88 M net.
Mutual funds holding Immix Biopharma, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Eventide Healthcare & Life Sciences FundEventide Asset Management, LLC3.89 M$40 M4.6%2.2%+53%Jun 30, 2026
🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc.2.10 M$22 M2.5%0.20%newJun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.78 M$18 M2.1%<0.01%+38%Jun 30, 2026
🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc.1.33 M$14 M1.6%0.11%+306%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors1.07 M$11 M1.3%0.01%newJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.681,413$7 M0.81%<0.01%+49%Jun 30, 2026
🇺🇸 Columbia Small Cap Value Discovery FundColumbia Management Investment Advisers, LLC483,630$4 M0.58%0.16%newJul 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors370,703$4 M0.44%0.02%newJun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC449,259$4 M0.54%0.01%newJul 31, 2026
🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc.357,034$3 M0.43%0.26%no changeJul 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC298,586$3 M0.36%<0.01%+158%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors138,125$1 M0.16%0.09%+59%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC109,438$1 M0.13%<0.01%+188%May 31, 2026
🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc.82,613$1 M0.10%0.11%+313%Jun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.99,794$1 M0.12%0.01%newJul 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC88,336$1 M0.11%<0.01%+190%May 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC76,786$1 M0.09%0.01%newJun 30, 2026
🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC71,495$1 M0.09%0.12%newJul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC44,723$0 M0.05%0.01%newJun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC54,609$0 M0.07%0.01%newJul 31, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC38,484$0 M0.05%0.03%newJun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.47,380$0 M0.06%<0.01%+73%Jul 31, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC33,534$0 M0.04%<0.01%newJun 30, 2026
🇺🇸 Columbia Variable Portfolio - Small Company Growth FundColumbia Management Investment Advisers, LLC30,390$0 M0.04%0.12%newJun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation29,800$0 M0.04%0.01%newJun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC36,034$0 M0.04%<0.01%newJul 31, 2026
🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC27,992$0 M0.03%0.11%+289%Jun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.22,835$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.22,585$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.21,124$0 M0.03%0.01%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC22,933$0 M0.03%<0.01%+36%May 31, 2026
🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC19,704$0 M0.02%0.12%+294%Jun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC16,780$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC16,780$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC19,540$0 M0.02%0.01%newJul 31, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC14,902$0 M0.02%0.01%newJun 30, 2026
🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc.14,396$0 M0.02%0.04%−4.1%Jun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.14,300$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC14,131$0 M0.02%0.01%newJun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC11,790$0 M0.01%0.01%newJun 30, 2026
🇺🇸 Multi-Manager U.S. Small Cap Equity FundGoldman Sachs Asset Management, L.P.10,622$0 M0.01%0.03%—Apr 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC9,203$0 M0.01%0.04%+49%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS9,166$0 M0.01%0.01%newJun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC8,523$0 M0.01%0.01%newJun 30, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust8,692$0 M0.01%<0.01%newMay 31, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.6,452$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC6,235$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.6,193$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC7,122$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC5,559$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC5,061$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.6,245$0 M<0.01%<0.01%+37%Jul 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC4,810$0 M<0.01%0.01%newJul 31, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC3,756$0 M<0.01%0.03%newJun 30, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management3,728$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 iShares Total U.S. Stock Market Index FundBlackRock Advisors, LLC4,611$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC3,284$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS3,633$0 M<0.01%0.01%newJul 31, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC2,863$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC3,543$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC1,848$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC1,435$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.1,037$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC872$0 M<0.01%<0.01%+39%Jun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC231$0 M<0.01%<0.01%+6.0%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 65 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Immix Biopharma, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$10 K
2 purchases, 2 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$10 K
open market only
Insiders on file
12
since
$267 K$0Dec 2023: bought $267 K (2 trades), sold $0 (0 trades)Dec 23May 2024: bought $20 K (2 trades), sold $0 (0 trades)Jun 2024: bought $17 K (4 trades), sold $0 (0 trades)JunJul 2024: bought $20 K (2 trades), sold $0 (0 trades)Aug 2024: bought $70 K (3 trades), sold $0 (0 trades)AugDec 2024: bought $104 K (2 trades), sold $0 (0 trades)Jun 2025: bought $10 K (2 trades), sold $0 (0 trades)JunSep 2025: bought $10 K (2 trades), sold $0 (0 trades)Dec 2025: bought $10 K (2 trades), sold $0 (0 trades)Dec
Bought (open market)Sold (open market)Hover a month for the totals
Immix Biopharma, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Jason HsuDirectorGrant or award+6,250——899,250Form 4
filed Carey NgDirectorGrant or award+6,250——26,250Form 4
filed Jane BuchanDirectorGrant or award+6,250——28,705Form 4
filed Helen C. AdamsDirectorGrant or award+6,250——181,004Form 4
filed Yekaterina ChudnovskyDirectorGrant or award+6,250——6,250Form 4
filed Magda MarquetDirectorGrant or award+6,250——52,342Form 4
filed Nancy T. ChangDirectorGrant or award+6,250——428,190Form 4
filed Ilya M. RachmanCEO and Chairman, DirectorBuy+746$6.670$5 K1.14 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Immix Biopharma, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
11.3 M
21.3% of shares · 9.24 days to cover
Buybacks, Q4 2022
$0M
Q4 2022
Shares sold short, last 24 reportsAll stocks →
Immix Biopharma, Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2022Q4 2022$0M
Q3 2022Q3 2022$0M

Fails to deliver

  • : 391 shares at $8.05
  • : 300 shares at $8.15
  • : 6,423 shares at $8.35
  • : 25 shares at $7.98
  • : 1,270 shares at $8.68

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Immix Biopharma, Inc. scorecard#

Passes 1 of the 12 checks that could be worked out. Fiscal year 2025; market cap of Oct 28, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median7.2×Price to book 7.2× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-3.7%Free cash flow is -3.7% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.89 vs -0.76Diluted EPS -0.89 in fiscal 2025 against -0.76 the year before (report's currency).
    • ✗Net income higher than five years earlier-$29 M-$29 M in fiscal 2025 against -$1 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$29 MNet income -$29 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-55.0%-55.0% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities10.0×Current ratio 10.01 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year16.6%Diluted shares up 16.6% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Immix Biopharma, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Immix Biopharma, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Research and development16118.74.20.10.2
General and administrative14117.44.01.20.2
Operating expenses3023168.21.40.5
Operating income−30−23−16−8.2−1.4−0.5
Interest and finance income0.61.00.6———
Interest expense and finance costs———0.00.20.1
Other non-operating income (expense)0.61.00.6−0.0−23−0.7
Income before tax−29−22−16−8.2−24−1.1
Income tax0.00.00.00.00.00.0
Net income including minority interests−29−22−16−8.2−24—
Minority interests' share of net income—−0.1−0.2———
Net income attributable to shareholders−29−22−15−8.2−24−1.1
Earnings per share, basic-0.89-0.76-0.89-0.59-6.64-0.34
Earnings per share, diluted-0.89-0.76-0.89-0.59-6.64-0.34
Shares, weighted average (basic)332817143.7—
Shares, weighted average (diluted)332817143.73.4
Balance sheet
Cash and cash equivalents94181813180.4
Short-term investments6.5—————
Other current assets0.20.00.00.1r0.50.0
Current assets101202015180.5
Property, plant and equipment2.51.70.10.00.00.0
Right-of-use (leased) assets1.01.0————
Total assets105232015180.5
Accounts payable5.45.41.40.1r0.10.3
Current liabilities108.73.71.30.25.3
Lease liabilities (non-current)0.91.0————
Total liabilities119.73.71.70.25.3
Retained earnings−104−75−53−38−30−5.4
Shareholders' equity9413161318−4.7
Minority interests——−0.2———
Total equity9413161318−4.7
Total liabilities and equity105232015180.5
Shares outstanding53282014133.4
Cash-flow statement
Share-based compensation2.43.02.60.6r0.2—
Cash from operating activities−24−15−11−7.4−1.6−0.4
Capital expenditure−0.7−1.2−0.1—−0.0—
Cash from investing activities−7.2−1.2−0.1—−0.0—
Shares issued10716162.919—
Shares bought back———−0.1——
Cash from financing activities10716153.219—
Exchange-rate effect on cash0.0−0.00.0−0.0−0.00.1
Change in cash760.24.1−4.217−0.3
Report10-K/A10-K/A10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where Immix Biopharma, Inc. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 4 subsidiaries on file.

Immix Biopharma, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office3 subsidiaries—
🇦🇺 Australia1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Events at Immix Biopharma, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling

Auditor changed 1 · Directors and officers 2 · Material agreement 5 · Unregistered share sale 2 · Shareholder vote 3 · Results announced 1

Immix Biopharma, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Shareholder vote8-K
Material agreement8-K
Material agreement8-K
Directors and officersMaterial agreementUnregistered share sale8-K
Shareholder vote8-K
Material agreement8-K
Auditor changed8-K
Directors and officersShareholder vote8-K
Unregistered share sale8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Lobbying by Immix Biopharma, Inc.#

$480 K spent on lobbying the US Congress and federal agencies in 2026, most often on health issues and medical/disease research/clinical labs.

Lobbying, 2026
$480 K
#577 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
5
in 2026
2026 so far
$480 K
  • Health Issues7 reports
  • Medical/Disease Research/Clinical Labs2 reports

Lobbying firms hired in 2026

CONTINENTAL STRATEGY, LLC $260 K · Tarplin, Downs & Young, LLC $100 K · AxAdvocacy Government Relations $80 K · YC Consulting, LLC $20 K · FIRST PRINCIPLES STRATEGIES, LLC $20 K

Immix Biopharma, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$480 K—10

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Immix Biopharma, Inc.”, “Immix Biopharma Inc” and “Immix Biopharma Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

Discuss Immix Biopharma, Inc.#

2 automatic updates and 0 member comments. Sign in to comment and react.

  • Results announced on 12 November 2026automatic update · Nov 12, 2026

    Immix Biopharma, Inc. announced results on 12 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $14 million.

  • Mutual funds: 65 funds hold $142 millionautomatic update · Jul 31, 2026

    65 mutual funds in 1 country hold shares of Immix Biopharma, Inc. worth $142 million, about 16.9% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 60 funds added shares and 1 sold; on balance they bought $88 million. Share splits are not counted as trading.

How Immix Biopharma, Inc. compares in Biotechnology

  • Market cap$675 M · higher than 62% of 726
  • Price / book7.2× · lower than 22% of 534
  • FCF yield-3.7% · higher than 75% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Immix Biopharma, Inc.🇺🇸$675 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 28, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of March 20, 2026
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Immix Biopharma, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Immix Biopharma, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Immix Biopharma, Inc.? Suggest a correction